Here are the 424B prospectus supplements from VivoSim Labs, Inc. (VIVS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VIVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VIVS filings page.
VivoSim Labs, Inc. is registering up to 3,508,772 shares of common stock (or up to 3,508,772 pre-funded warrants in lieu thereof) and related warrants, plus placement agent warrants, in a best-efforts offering comprised of two tranches.
The Initial Tranche covers the sale of 286,557 shares and 2,345,022 pre-funded warrants (with 1.5 common warrants per share/pre-funded warrant) at combined prices of $1.14 and $1.139, respectively, and common warrants issued with a $1.71 exercise price. A Second Tranche of up to $1,000,000 may close 30 days later if specified market-volume and price conditions are met. The common warrants are immediately exercisable, expire five years after issuance, permit cashless exercise (subject to a Black‑Scholes formula and a $0.01 floor), and the company is registering up to 250% of shares issuable upon exercise to help cover potential cashless exercises. Proceeds are intended for working capital and general corporate purposes; estimated net proceeds from the Initial Tranche are approximately $3.3 million after placement agent fees and expenses.